Mizuho raised the firm’s price target on Boston Scientific to $60 from $56 and keeps a Neutral rating on the shares following the analyst day. The company offered a fresh long-range plan that aims for number one top- and bottom-line growth positioning versus its large-cap peers over the next three years, the analyst tells investors in a research note. The firm believes Boston Scientific’s will be supplemented by modest price tailwinds, consistent underlying volume growth in core verticals, and tuck-in acquisitions. However, “slowly churning” GLP-1 and China headwinds keep it Neutral rated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BSX:
- Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
- Boston Scientific signs agreement to acquire Relievant Medsystems
- Boston Scientific has ‘compelling’ pipeline ahead of investor day, says CL King
- Boston Scientific’s Watchman FLX device approved by FDA
- Unusually active option classes on open August 29th